The Business Research Company’s report on the Liver Cirrhosis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the liver cirrhosis market’s growth in recent years?
The increase in alcohol consumption is expected to propel the growth of the liver cirrhosis market going forward. Alcohol consumption refers to the intake of alcoholic beverages, typically measured in terms of quantity and frequency. People are increasingly consuming alcohol because it helps them unwind from daily stress, fosters social connections in gatherings, and enhances moments of relaxation, while also being widely promoted through media and becoming more accessible in various settings. Liver cirrhosis treatment for patients with excessive alcohol consumption focuses on managing liver damage through abstinence, medications, and supportive care while addressing alcohol dependence with counseling and rehabilitation. For instance, in March 2023, according to the National Drugs Library, an Ireland-based data collection organization, in 2022, the average alcohol consumption for individuals over 15 years old rose to 10.2 liters of pure alcohol per capita, reflecting a 7.6% increase from 2021. Therefore, increasing alcohol consumption drives the liver cirrhosis market.
Access Your Free Sample of the Global Liver Cirrhosis Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22040&type=smp
How does the future projection of the liver cirrhosis market size compare to its historical growth?
The liver cirrhosis market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing prevalence of liver diseases, high alcohol consumption, an aging population, increased healthcare expenditure, and increasing government initiatives.
The liver cirrhosis market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to the rising incidence of hepatitis infections, rising economic growth, increasing urbanization, lifestyle changes, and growing medical tourism. Major trends in the forecast period include advancements in diagnostic tools, technological innovations, collaborations and partnerships, integration of artificial intelligence, and integration of holistic therapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22040&type=smp
Which key players are shaping the future of the liver cirrhosis market?
Major companies operating in the liver cirrhosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Viatris Inc., Grifols Therapeutics LLC, Shionogi Inc., Galectin Therapeutics Inc., NGM Biopharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Akero Therapeutics Inc.
What trends will propel the growth and evolution of the liver cirrhosis market?
Major companies operating in the liver cirrhosis market are focusing on advancements in treatment options, such as the development of the active implantable medical devices, to improve patient outcomes and expand therapeutic possibilities. Active implantable medical devices are electronically powered implants designed to monitor, support, or improve organ function within the body. For instance, in December 2024, Sequana Medical NV, a Belgium-based medical device company, received the U.S. FDA approval for its alfapump system, the first active implantable medical device in the U.S. for managing recurrent or refractory ascites caused by liver cirrhosis. This breakthrough technology offers a continuous, automated solution for fluid management by transferring excess abdominal fluid to the bladder, significantly reducing dependence on invasive therapeutic paracentesis. Alfapump represents a major advancement in improving patient outcomes and enhancing quality of life with an addressable market of approximately 70,000 patients in the United States.
Which regions are expected to become dominant players in the liver cirrhosis market?
North America was the largest region in the liver cirrhosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cirrhosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/liver-cirrhosis-global-market-report
What are the emerging key segments in the liver cirrhosis market, and how are they evolving?
The liver cirrhosis market covered in this report is segmented –
1) By Type: Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis
2) By Treatment: Antibiotics, Immunosuppressants, Other Treatments
3) By End Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Alcoholic Cirrhosis: Compensated Alcoholic Cirrhosis, Decompensated Alcoholic Cirrhosis, Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
2) By Atrophic Cirrhosis: Post-necrotic Atrophic Cirrhosis, Macronodular Atrophic Cirrhosis, Micronodular Atrophic Cirrhosis
3) By Biliary Cirrhosis: Primary Biliary Cirrhosis (PBC), Secondary Biliary Cirrhosis, Autoimmune Biliary Cirrhosis
4) By Cardiac Cirrhosis: Right Heart Failure-Induced Cirrhosis, Chronic Passive Congestion Cirrhosis, Ischemic Hepatitis Cirrhosis
5) By Cryptogenic Cirrhosis: Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis, Idiopathic Cirrhosis, Metabolic Syndrome-Associated Cirrhosis
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22040
What defines the structure and scope of the liver cirrhosis market?
Liver cirrhosis is a progressive disease in which healthy liver tissue is gradually replaced by scar tissue, impairing the liver’s ability to function properly. This condition results from prolonged liver damage caused by factors such as chronic alcohol consumption, viral hepatitis, or fatty liver disease.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
